Project Grant R21AI196618
Award Date 8/4/26
Completion Date 7/31/28
Dollars Obligated $336K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded ST Jude Children's Research Hospital Inc. $880,417 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define regulatory T cell repertoire sustainability and dynamics. The research investigates how regulatory T cells (Tregs) maintain a diverse repertoire of T cell antigen receptors (TCRs) over time, addressing gaps in understanding Treg repertoire dynamics, sustainability, and...
- The National Institute of Allergy and Infectious Diseases awarded St Jude Children's Research Hospital Inc. $867,054 on May 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to mechanistically define bacterial and host factors underlying vaccine-escape infection in Streptococcus pneumoniae serotype 3, develop tailored protein-based vaccines to prevent breakthrough infections, and produce mathematical models predicting vaccine efficacy across bacterially and...
- The National Institute of Allergy and Infectious Diseases awarded St. Jude Children's Research Hospital Inc. $151,040 on March 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on strategies and consequences of polymicrobial nasal colonization. The research investigates how polymicrobial interactions within the upper respiratory tract impact a pathogen's ability to colonize and cause infection. The project focuses on how respiratory pathogens...
- The National Institute of Allergy and Infectious Diseases awarded ST Jude Children's Research Hospital Inc. $159,560 in project grant funding on October 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the determinants of fluconazole resistance evolvability in Candida auris, an emerging multidrug-resistant fungal pathogen. The research investigates the biological mechanisms underlying the high frequency of acquired resistance...
- The National Institute of Allergy and Infectious Diseases awarded St Jude Children's Research Hospital Inc. $508,750 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a method for engineering high-fidelity regulatory T cells as a living therapeutic agent for immunological diseases including type I diabetes and multiple sclerosis. The research addresses the instability of regulatory T cells (Tregs) in inflammatory conditions, where they lose...
- The National Institute of Allergy and Infectious Diseases awarded ST Jude Children's Research Hospital Inc. $277,500 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer a synthetic IL-33 receptor that enhances T-cell function for treating autoimmune disorders and cancer. The research systematically examines regulatory nodes governing T-cell differentiation and function, including environmental cues, signaling pathways, metabolism,...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $3.43 million Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 22, 2025, through June 30, 2029. The award supports fundamental biomedical research investigating epigenetic checkpoint regulation of naive T-cell quiescence and peripheral tolerance—specifically examining how the ascorbate transporter...
- The National Institute of Allergy and Infectious Diseases awarded the Children's Hospital of Philadelphia $889,516 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the Antibiotic Drug Exposures and Endotracheal Pharmacokinetics (DEEP) study. The research aims to understand factors governing antibiotic delivery to the lower respiratory tract in critically ill children, examine how antibiotic concentrations relate to changes in the...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $448,292 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of ceftazidime-avibactam in combination with meropenem in the prevention and treatment of mutant KPC-producing infections using a hollow fiber infection model. KPC-producing Enterobacterales infections carry mortality rates upwards of 40 percent....
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $800,557 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host defense. The funded research identifies mechanisms by which diverse S. aureus strains, including toxigenic and non-toxigenic variants, activate inflammasome regulatory proteins in immune cells....